We have previously reported that the human transforming growth factor-a (TGF-a) gene encodes three forms of TGF-a precursors, designated wild type (WT), variant I (VaI), and variant II (VaII), derived from alternative splicing. The two carboxyl-terminal valine residues of WT are replaced by 5 (GCRLY) or 4 (ATLG) amino acids in VaI or VaII, respectively. When overexpressed in Chinese hamster ovary (CHO) cells, VaI and VaII, but not WT, support autonomous growth. We detected tyrosine phosphorylation of ErbB2 in the absence of serum, in CHO cells expressing WT, VaI, or VaII, but not in mock transfectants. These observations prompted us to investigate possible interactions between the ErbBs and the TGF-a precursors in CHO cells. All TGF-a precursors were found to co-immunoprecipitate with the ErbBs, but with dierent speci®city. WT co-immunoprecipitated with ErbB4, but not with ErbB1, ErbB2, or ErbB3. VaI and VaII co-immunoprecipitated with ErbB2, but not with ErbB1, ErbB3, or ErbB4. Confocal uorescent microscopy analysis demonstrated that WT, VaI, and VaII all distribute equally to the cell surface while, as expected, a WT mutant lacking the two Cterminal valine residues does not. Point and deletion mutants involving the unique carboxyl-terminal residues of WT, VaI and VaII, indicated that the interactions between the three TGF-a precursors and the ErbBs were mediated by their carboxyl-terminal regions, which constitute distinct protein-binding motifs. A chimera of the intracellular domain of WT TGF-a linked to exogenous transmembrane and extracellular domains retained both the cell surface distribution and the speci®c interaction with ErbB4 of full-length WT, con®rming that this interaction is mediated by the C-terminus of the TGF-a precursor. While interactions of WT and variant TGF-a with the ErbBs all result in ErbB2 activation, they produce dierent biological consequences, suggesting that the various TGF-a precursors dierentially modulate ErbB signaling. Oncogene (2000) 19, 3172 ± 3181.
Introduction
The ErbB family includes four receptor tyrosine kinases, namely the epidermal growth factor receptor (EGFR, or ErbB1), ErbB2 (Neu), ErbB3, and and ErbB4, of which the EGFR is the prototype (for recent reviews, see Alroy and Adamson and Wiley, 1997) . All four structurally homologous receptors include an extracellular ligand-binding domain, a single hydrophobic transmembrane domain, and, with the exception of ErbB3, an intrinsic tyrosine kinase domain (Guy et al., 1994) . Aberrant expression of the ErbB receptors has been associated with several types of human cancers, particularly breast cancers (Cohen et al., 1998) . For example, numerous studies demonstrate that about 20 ± 30% of breast cancer patients overexpress ErbB2, in the presence or absence of gene ampli®cation. Overexpression of ErbB2 is a predictor of poor survival and short time to relapse, and correlates with high resistance to chemotherapy (Cohen et al., 1998) . In one recent study (Shackney et al., 1998) , about 50% of breast cancer patients with ErbB2 overexpression also had aberrant levels of EGFR. Overexpression of ErbB4, along with that of ErbB2 in human medulloblastoma, is an independent prognostic factor for patient survival (Gilbertson et al., 1997) .
The EGF-like polypeptides constitute the ligands for the ErbB receptors. There are at least two dierent categories of EGF-like ligands: ErbB1 ligands, including EGF, transforming growth factor-a (TGF-a), heparin-binding epidermal growth factor-like factor (HB-EGF), amphiregulin, epiregulin (EPR), b-cellulin (BTC); and the neuregulins (NRGs), including NRG-1, NRG-2, NRG-3, NRG-4, which are ligands for ErbB3 and ErbB4 (Massague and Pandiella, 1993; Lee et al., 1995) . BTC, HB-EGF, and EPR also bind to ErbB4 and promote ErbB4 to form dimeric complexes (Riese et al., 1996a (Riese et al., ,b, 1998 . Most EGF family peptides are synthesized as transmembrane precursors, proteolytically cleaved to release the mature soluble factors. The transmembrane-bound precursors share no obvious homology with each other, except for an EGF-like domain. This domain is sucient to bind to and activate ErbB receptors. Formation of homo-or heterodimeric complexes of ErbB receptors induced by ligand binding results in activation of ErbB receptors, thus triggering downstream signaling cascades to relay the extracellular stimuli into the nucleus. ErbB2 is considered the preferred and common auxiliary partner for the formation of heterodimers with the other three ErbB receptors (Klapper et al., 1999) . Heterodimeric complexes containing ErbB2 have potent signaling activity, apparently due to the ability of ErbB2 to decelerate the rate of ligand dissociation Wang et al., 1998) .
Although ErbB2 shares extensive structural homology with ErbB1 and ErbB4, along the catalytic intracellular domain and in the extracellular putative ligand-binding region, many attempts to identify a high anity ligand for ErbB2 have failed (Dougall et al., 1994) . TGF-a binds to and activates the EGFR. The activated EGFR in turn trans-modulates ErbB2 activity. However, recombinant TGF-a does not bind to ErbB2 when over-expressed in a de®ned cell system lacking any endogenous ErbBs (Wang et al., 1998; Riese et al., 1996b) . Interestingly, Muller and colleagues (1996) have observed a synergistic interaction of TGF-a and Neu (ErbB2) in mammary tumorigenesis, in double transgenic mice. Activated EGFR and physical association of Neu and EGFR were barely detectable in two of the four double transgenic mice (Muller et al., 1996) , suggesting that activation of ErbB2 by TGF-a can be either dependent on or independent of EGFR activation. Conditional expression of ErbB2 under the control of the keratin 14 promoter results in a 10-fold up-regulation of TGF-a expression in transgenic mice (Xie et al., 1999) . These observations suggest some functional association between TGF-a and ErbB2 independent of the EGFR.
The TGF-a precursor has been a model molecule for exploring possible functional roles of the intracellular portion of the EGF-like ligand precursors. The carboxyl-terminal valine residue is important for intracellular tracking and maturation of the TGF-a precursor (Briley et al., 1997; Urena et al., 1999) . The cytoplasmic tail of the wild type TGF-a precursor (WT) has also been reported to physically associate with a protein complex possessing both tyrosine kinase and serine/threonine kinase activity (Shum et al., 1994 (Shum et al., , 1996 . This association suggests that WT TGF-a precursor may have a signaling function. The carboxyl terminal TVV motif is recognized by PDZ-domain containing proteins, including syntenin and a1-syntrophin (Fernandez-Larrea et al., 1999) . A distinguishing feature of PDZ domains is their recognition of short peptides with a carboxyl hydrophobic residue and a free carboxylate group, as exempli®ed by the (S/T)XV motif at the carboxyl-terminus of certain membranebound proteins (Songyang et al., 1997) . PDZ domains also recognize related carboxy-terminal motifs such as VKI, YYV, VX(V/A), and IQL (Torres et al., 1998) . Additionally, proteins with PDZ domains frequently contain other interaction modules, including SH3 and LIM domains, and catalytic elements such as protein tyrosine phosphatase (Pawson and Scott, 1997) . PDZ domains mediate the formation of protein complexes at the plasma membrane (the basolateral or the apical membrane) including clustering of transmembrane receptors, and organization of the components of cellular signaling pathways (Fanning and Anderson, 1999) . Syntenin was demonstrated to interact with immature TGF-a precursor through the carboxylterminus, TVV, in the early secretory pathway (Fernandez-Larrea et al., 1999) . This interaction supports the idea that the carboxyl-terminus is important for intracellular tracking and maturation of WT TGF-a.
We have previously isolated two variant TGF-a precursors derived from alternative splicing, designated as VaI and VaII (Xu et al., 1999) . The two carboxylterminal valine residues in WT are replaced by ®ve (GCRLY) or four (ATLG) amino acids in VaI and VaII, respectively. Both variants, but not WT, support autonomous growth of CHO cells at clonal density, therefore we reasoned that there may be some functional association between the various TGF-a precursors and the ErbBs in these cells. In this report, we demonstrate that CHO cells express detectable levels of endogenous ErbB2 and ErbB4, but not ErbB1 or ErbB3. Co-immunoprecipitation assays demonstrated that WT interacted with endogenous ErbB4, but not with ErbB2, or exogenous ErbB1 or ErbB3. On the other hand, VaI and VaII co-immunoprecipitated with ErbB2, but not with ErbB1, ErbB3 or ErbB4. Deletion mutagenesis analysis demonstrated that these interactions were mediated by the unique carboxyl termini of the three forms of TGF-a precursors. Further mutagenesis analysis within the unique carboxyl-termini of the three TGF-a precursors suggests that these carboxyl-termini constitute three dierent protein-binding motifs. A chimeric construct containing the C-terminus of WT and heterologous transmembrane and extracellular domains retained a speci®c interaction with ErbB4. Despite the fact that all three TGF-a precursors produce ErbB2 activation in the absence of serum in CHO cells, they have distinct biological activities suggesting that they aect ErbB2 signaling in dierent ways.
Results
ErbB2 phosphorylation in the absence of serum in CHO cells expressing WT or TGF-a variants VaI or VaII CHO cells express low levels of endogenous ErbB2, but not ErbB1 or ErbB3 . We reasoned that the growth advantage provided to CHO cells by TGF-a VaI and VaII (Xu et al., 1999) might be mediated through ErbB2 activation. However, it has been demonstrated that mature TGF-a does not bind to and activate ErbB2, and no high-anity ligand so far has been identi®ed for ErbB2. The amino acid sequences of the intracellular domains of human ErbB2 and hamster ErbB2 (Nakamura et al., 1994) (http:// dot.imgen.bcm.tmc.edu:9331) are more than 92% identical and 95% similar, and the epitope for a polyclonal antibody raised against human ErbB2 (UBI) is identical to hamster ErbB2 (data not shown). Therefore, we used this antibody to detect endogenous ErbB2 in CHO cells (Figure 1a) . We determined that expression of HA-tagged TGF-a precursors in CHO cells did not aect the expression levels of total endogenous ErbB2 (Figure 1a) . However, when CHO cells expressing the TGF-a precursors and mock transfectants were starved in serum-free medium for 24 h, we observed that ErbB2 was phosphorylated on tyrosine in CHO cells expressing the TGF-a precursors, but not in mock transfectants (Figure 1b) . When the starved cells were re-stimulated by medium containing 10% serum for 1 h, ErbB2 phosphorylation was induced in mock transfectants as well (Figure 1b) . Surprisingly, ErbB2 phosphorylation levels were not signi®cantly dierent between CHO cells expressing WT and variant TGF-a precursors, despite the fact that VaI and VaII reduced serum requirements, and VaII (but not VaI or WT) exhibited transforming abilities (Xu et al., 1999) . Nevertheless, this observation suggested a possible association between the TGF-a precursors and the ErbB2 receptor.
Both variants, but not the wild type TGF-a precursor, interact with endogenous ErbB2 in CHO cells and this interaction requires their unique carboxyl termini
We then sought to identify any physical association between ErbB2 and the HA-tagged TGF-a precursors. ErbB2 immunoprecipitates from CHO cells expressing TGF-a precursors and mock transfectants were probed with a monoclonal anti-HA antibody. The ErbB2 receptor co-immunoprecipitated with VaI and VaII, but not WT (Figure 2 ). When CHO clones with similar expression levels of VaI and VaII were used, it was demonstrated that both variants interact with ErbB2 to a similar level (data not shown). No mature TGF-a, which is HA-tagged and should migrate at about 6 kDa, was detected in the ErbB2 immunoprecipitates (data not shown). WT, although expressed at high levels in the CHO clone used in this experiment ( Figure  2a ), did not interact with ErbB2 (Figure 2b ). These observations, together with the fact that the only dierence among the three TGF-a forms lies in their carboxyl-termini, strongly indicated that the unique carboxyl-termini of the variant TGF-a precursors mediated the interaction with ErbB2. We then constructed a deletion mutant, VVDEL, which removed the extreme two carboxyl-terminal valine residues of WT, retaining all the peptide sequences common among the three forms of TGF-a precursors. As shown in Figure 2b , the association between VVDEL and ErbB2 was signi®cantly decreased in comparison to the association between VaII and ErbB2. Interestingly, and as we will discuss in more detail later, an alanine for threonine substitution in the C-terminal sequence of VaII also abolished ErbB2 binding ( Figure 2b , VaIIT?A). The interactions between variants and ErbB2 may account for the ErbB2 phosphorylation in CHO cells expressing variant TGF-a in the absence of serum. However, ErbB2 phosphorylation in CHO cells expressing WT in the absence of serum remained puzzling.
CHO cells express endogenous ErbB4
ErbB4 is the newest member of the ErbB receptor family (Plowman et al., 1993) , and it is believed to be predominantly located in neurons, glia, and heart (Adamson and Wiley, 1997). In an attempt to examine the possible association between the TGF-a precursors and ErbB4, the vector pBABE-ErbB4-puro was introduced into CHO cells expressing the TGF-a precursors and mock transfectants. Western blot analysis with polyclonal antibodies targeting the carboxyl-terminus of human ErbB4 (C-18) detected a signal in CHO cells, which migrated identically to the ErbB4 receptor in C33A cells. This signal was much more intense when CHO cells expressed exogenous ErbB4 (Figure 3a) . The exact sequence of hamster ErbB4 has not been determined, but the ErbBs are so well conserved that one can reasonably assume that the band detected by the anti-human ErbB4 antibodies in CHO cells is endogenous ErbB4. We failed to detect ErbB1 in CHO cells by Western blot analysis with a variety of anti-EGFR antibodies. In addition, Western blot analysis with anti-phosphotyrosine antibodies of ErbB2 in CHO cells expressing TGF-a precursors is tyrosinephosphorylated in the absence of serum. Duplicate sets of CHO transfectants were cultured to 80% con¯uency and then starved in serum-free medium for 24 h. Serum-free medium in one set of CHO cells was replaced by complete medium containing 10% serum. These cells were cultured for an additional hour. Total lysates from these CHO cells were immunoprecipitated with the anti-ErbB2 antibody (C-18). The immunoprecipitates were probed with the pY plus antibodies for the detection of phosphotyrosinecontaining proteins were subjected to Western blot analysis using an anti-HA antibody to assess the expression levels of HAtagged TGF-a and mutant proteins. (b) Duplicate sets of these CHO transfectants were cultured to 80% con¯uency and then starved in serum-free medium for 24 h. One set was immediately used for lysate extraction; the other was cultured in the medium containing 10% serum for 1 h followed by lysate extraction. Total cell lysates (400 mg protein) were immunoprecipitated with a polyclonal anti-ErbB2 antibody. The immunoprecipitates were subjected to Western blot analysis with an anti-HA monoclonal antibody, for the detection of HA-tagged TGF-a WT, variant and mutant precursors CHO cells treated with EGF after serum starvation failed to reveal any phosphorylated proteins, again indicating that (as expected) CHO cells are devoid of functional ErbB1 receptors (data not shown).
The wild type TGF-a precursor interacts with ErbB4, and this interaction is mediated by the carboxyl-terminal valine residues
We next explored the possibility of an association between endogenous ErbB4 and HA-tagged TGF-a precursors by co-immunoprecipitation assays in CHO cells. HA-tagged TGF-a precursor was detected in antiErbB4 immunoprecipitates from CHO cells expressing WT, but neither variants nor VVDEL, or the VaIIT?A mutant (Figure 3b,c) . These results show that WT interacts with ErbB4, and suggest that the carboxyl-terminal valine residues of WT are required for this interaction. This interaction may account for ErbB2 phosphorylation in the absence of serum, if it promotes ErbB2/ErbB4 heterodimerization in CHO cells expressing WT. However, ErbB2 phosphorylation does not correlate with autonomous growth of CHO cells expressing TGF-a precursors. Therefore, activation of ErbB2 by WT and variant TGF-a precursors may relay dierent signals to the nucleus.
To con®rm that the interaction between the TGF-a precursors and the ErbBs was mediated by the Cterminus, we constructed chimeric constructs containing an arti®cial uncleavable extracellular domain (thè Hook' moiety) and the transmembrane and/or cytoplasmic domain of the various TGF-a precursors ( Figure 4a ). The Hook molecule is derived from the pHook-2 construct (Invitrogen), which encodes a hapten-binding single-chain antibody (phOx sFv) with a signal peptide (SP) and a HA tag at its amino terminus, and two Myc tags and the platelet derived growth factor (PDGF) receptor transmembrane domain at its carboxyl-terminus. We produced two series of chimeric constructs: in the TACT constructs the intracellular domain of the TGF-a precursors is linked to the transmembrane domain of the pHook construct, derived from the PDGF receptor (Figure 4a , TACT). In the second series, the transmembrane and intracellular moiety of the TGF-a precursors were linked to the Hook moiety devoid of the PDGF receptor transmembrane domain (Figure 4a , TMCT). Using these constructs, we determined that the interaction between WT and ErbB4 is speci®c and requires the WT C-terminal domain (Figure 4b) . Surprisingly, while the WT pHook construct had no eect on ErbB2 or ErbB4 levels, pHook constructs containing variant TGF-a intracellular domains caused a marked decrease in ErbB2 levels detected by Western blot analysis, making it impossible to assess whether they retained their interactions with ErbB2 (data not shown).
Wild type and variant TGF-a precursors traffic equally to the cell surface
We examined the subcellular distribution of WT and variant TGF-a precursors by immuno¯uorescence and confocal microscopy analysis using an anti-HA antibody, and a secondary antibody conjugated with thē uorescent label Alexa Fluor TM 488, as described in Materials and methods. Cells were serum-starved for 12 h, ®xed in buered formalin, and either permeabilized with Triton X-100 (Figure 5a ± e) or directly incubated with the anti-HA antibody, without permeabilization (Figure 5f ± j). We detected abundant surface staining in non-permeabilized CHO cells expressing WT or variant TGF-a precursors, but not in CHO expressing the VVDEL mutant. As expected based on our previous processing data (Xu et al., 1999) treatment with calcium ionophore dramatically decreased cell surface (and also total) staining in WT, VaI and VaII constructs (data not shown). CHO expressing the`Hook' moiety alone, or the chimeric TACT-WT and TMCT-WT constructs also exhibited abundant cell surface staining with the anti-HA antibody indicating that the TACT-WT and TMCT-WT trac normally to the cell surface (data not shown).
The unique carboxyl-termini of TGF-a precursors consist of three different protein-binding motifs The VVDEL deletion mutant, which retains all the common sequences among the three TGF-a precursors, signi®cantly weakened the interaction between variants and ErbB2 (Figure 2) , and abolished that of WT and ErbB4 (Figure 3c ). In addition, a chimeric construct containing just the C-terminal region of WT retained its interaction with ErbB4 (Figure 4) . These results suggest that interactions with the ErbBs are mediated through the unique carboxyl-termini of the TGF-a precursors. In other words, the unique carboxyl-termini of the TGF-a precursors may consist of dierent protein-recognition motifs. Therefore, we generated a series of deletion and point mutants targeting the carboxyl-terminal residues of the three TGF-a precursors (Figure 6 ). These mutant constructs were transfected into CHO cells by the calcium phosphate precipitation method. We screened for individual clones expressing appropriate levels of HA-tagged mutant proteins by Western blot analysis (Figure 7a ).
The carboxyl-terminal sequence TVV in the wild type TGF-a precursor corresponds to a PDZ proteinbinding motif, (S/T)X(V/L) (Songyang et al., 1997) . Recently, it was reported that WT interacted with two PDZ-domain proteins, namely syntenin and a1-syntrophin through the TVV sequence (Fernandez-Larrea et al., 1999) . The interaction between WT and syntenin occurs in the early secretory pathway and aects the maturation of WT TGF-a (Fernandez-Larrea et al., 1999) . We removed the extreme carboxyl-terminal valine residue of WT, generating a mutant that retains Figure 5 Immuno¯uorescence and confocal microscopy of permeabilized (P) or non-permeabilized (NP) CHO cels expressing the indicated TGF-a precursors. Stable transfectants of HA-tagged TGF-a wild type (WT), variant (VaI or VaII) and VV deletion mutant (VVDEL) constructs in CHO cells were grown on glass coverslips, serum starved for 12 h, ®xed in 3.7% Formaldehyde in PBS and permeabilized with 0.1% Triton X-100 prior to immunostaining (a ± e) or directly stained without permeabilization to visualize surface-bound TGF-a precursors (f ± j). Immunostaining was performed using a rat monoclonal anti HA antibody and a secondary antibody conjugated with the¯uorochrome Alexa Fluor TM 488 (Molecular Probes). Fluorescence was visualized by a BioRad MRC 1024 Laser Scanning Confocal Imaging System coupled to a Nikon Optiphot 1 confocal microscope one valine at its carboxyl-terminus (WTDV, Figure 6 ). This deletion mutant abolished the interaction with ErbB4 ( Figure 7b ). This observation indicates that the TVV motif, the PDZ protein-binding site, is necessary for the interaction between WT and ErbB4.
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Thr in the carboxyl-terminus of VaII could be part of a PDZ domain recognition motif (Songyang et al., 1997) . On the other hand, Gly at the extreme carboxyl-terminus, which is a non-polar amino acid without any side chain, does not ®t into the crystallographic structure of PDZ domains (Doyle et al., 1996) . Nevertheless, we generated a point mutant ( (Figures 2b and 3c , VaIIT?A). This result indicated to us that the threonine residue may play an important role in mediating the interaction with ErbB2. However, using deletion mutants, we did not observe a signi®cant loss of interaction until two amino acids from the carboxyl-terminus were deleted (VaIID2) (Figure 7c ) although any deletion changes the relative position of the threonine residue, which would be critical for PDZ protein binding.
The carboxyl-terminal peptide GCRLY in VaI contains a consensus prenylation site (Xu et al., 1999) where the cysteine residue could be the prenylation acceptor site (Zhang and Casey, 1996) . Therefore, we generated a VaI point mutant in which 160 Cys was mutated to 160 Ala, and a series of deletion mutants removing a single amino acid at a time from the extreme carboxyl-terminus of VaI: VaIC?A, VaID1, VaD2, VaID3, and VaID4 (Figure 6 ). Although the mutant protein levels were higher than VaI (Figure 7d ), we could not detect an association between ErbB2 and any of the mutants (Figure 7e ). These data strongly argue that the unique carboxyl-terminus of VaI may constitute a recognition motif which requires all ®ve amino acids. Since the point mutation of 160 Cys to 160 Ala abolished the interaction, it is possible that the carboxyl-terminus of VaI is a functional prenylation site.
ErbBs 1 or 3, when overexpressed in CHO cells expressing TGF-a precursors, do not associate with either TGF-a precursor
Our results indicate that the unique carboxyl-termini of the three TGF-a precursors constitute three dierent protein-binding motifs, which interact with ErbB2 and ErbB4. To determine if there was any association Cys of VaI is critical for the interaction with ErbB2. Total cell lysates (500 mg protein) from CHO transfectants were immunoprecipitated with an anti-ErbB2 antibody. The precipitates were probed with an anti-HA antibody in a Western blot analysis between the TGF-a precursors and ErbB1 or ErbB3, the other two members of the ErbB receptor family, we transfected CHO cells expressing HA-tagged TGF-a precursors with ErbB1 cDNA (in the pcDNA/Zeo vector) or ErbB3 cDNA (in the retroviral vector pBabe-puro). Despite robust expression of the two ErbBs, we failed to observe any association between the TGF-a precursors and ErbB1 or ErbB3 in coimmunoprecipitation assays (data not shown).
Discussion
In this study, we demonstrate that the WT TGF-a precursor interacts with the intracellular domain of ErbB4. This interaction is mediated by the TVV motif at the extreme carboxyl-terminus of WT. However, at this point we do not know whether this interaction is direct, or involves other bridging proteins. Recent data have demonstrated that the carboxyl-terminus (TVV) of WT interacts with two PDZ-domain containing proteins, namely syntenin and a1-syntrophin (Fernandez-Larrea et al., 1999) . It is interesting to note that the extreme carboxyl-terminus of ErbB4 is also TVV, the targeting motif for PDZ domains. Therefore, if there is an adaptor protein mediating the interaction between WT and ErbB4, this protein may belong to the PDZ domain family.
We failed to detect an interaction between the EGF receptor and the TGF-a precursors. We interpreted this to indicate that the interaction between the EGF receptor and its ligand is too transient to be detected under the conditions of our co-immunoprecipitation assays. This observation and the lack of an interaction with ErbB3 further support the interpretation that the interactions we observed between TGF-a precursors and ErbB2 and ErbB4 are much more stable, and are speci®c for those ErbBs.
Both variant TGF-a precursors have carboxyl termini very dierent from that of WT (Xu et al., 1999) and were found to co-immunoprecipitate with ErbB2 but not with ErbB4. Deletion mutants targeting the unique carboxyl-termini of both variants indicate that the interaction between the variants and ErbB2 requires intact carboxyl-terminal peptides. There is no evident structural similarity between the two carboxyl termini, therefore, although both target ErbB2, they may constitute two dierent protein-interaction motifs targeting dierent subdomains within the cytoplasmic domain of ErbB2. It is possible that the interaction between variant TGF-a precursors and ErbB2 may be mediated by other bridging proteins. The carboxylterminus of either the human ErbB2 or the hamster ErbB2 is VPV, a PDZ-domain binding motif (Torres et al., 1998) . Therefore, if a bridging protein between the TGF-a precursors and ErbB2 is necessary, it may be a PDZ-domain containing protein. Additionally, the carboxyl-terminus of VaI contains a possible prenylation site. Point mutation of the cysteine residue, which is the prenylation acceptor site, essentially abolished the interaction of VaI with ErbB2, indicating prenylation may play a role in mediating this interaction.
CHO cells were thought to express endogenous ErbB2, but not any other ErbB receptor . In this study, we demonstrated that CHO cells express ErbB4 as well. In addition, when we examined the mRNA expression patterns of ErbB receptors by RPA in a variety of human tumor-derived cancer cell lines, normal keratinocytes, and keratinocytes immortalized by HPV16 DNA, we found that each cell line examined expresses at least two members of the ErbB family (Xu and Pirisi, unpublished observation) . This suggests that ErbB heterodimerization is essential for cell proliferation and dierentiation.
It has been well documented that exogenous TGF-a does not bind to and activate ErbB2 or ErbB4, when each receptor is overexpressed alone (Riese et al., 1996b; Wang et al., 1998) . Riese and colleagues (1996b) showed that exogenous TGF-a could not activate either ErbB2 or ErbB4 when both were overexpressed in Ba/F3 cells. However, in 32D cells overexpressing both ErbB2 and ErbB4 receptors, TGF-a induced phosphorylation of both receptors and elicited a mitogenic eect (Wang et al., 1998) . In this study we have observed that endogenous ErbB2 in CHO cells expressing all TGF-a precursors, but not the mock transfectants, was tyrosine phosphorylated in the absence of serum. This ®nding indicated at least two possibilities. First, the ErbB2/ErbB4 combination, like the ErbB2/ErbB3 combination (Alimandi et al., 1997; Pinkas-Kramarski et al., 1998) may display an extended speci®city to ErbB1 ligands. Second, both variant TGF-a precursors may activate ErbB2 receptor in a way requiring intracellular interaction between the variants and ErbB2. However, several lines of evidence suggest to us that the consequences of the interactions between the various TGF-a precursors and the ErbBs are dierent: (1) The ability to support autonomous growth of CHO cells is exhibited by VaI and VaII, but not WT; (2) Induction of focus formation and morphological changes were observed with VaII, but not WT or VaI. (3) In addition, while CHO expressing VaII are stable and maintain high levels of expression through passaging, CHO expressing VaI or WT progressively lose the TGF-a precursor. For this reason, we documented by Western blot analysis the levels of proTGF-a expression at each experiment, in each CHO clone used to investigate interactions with the ErbBs (Figures 1, 2, 3 and 7) . This observation indicates that expression of VaII confers a growth advantage to CHO cells both in the presence and in the absence of serum (see also Xu et al., 1999) . However, overexpression of WT or VaI may be detrimental to CHO cell proliferation (at least in 10% serum) and cells with high levels of expression of these TGF-a forms may be selected against during long-term culturing. This also indicates that the functional dierences between the various forms of TGF-a precursors may be manifest depending in part on the nature and availability of exogenous growth factors.
Our immuno¯uorescence and confocal analysis data con®rmed the ®nding that a deletion of the C-terminal Val residues profoundly aects tracking of the WT TGF-a precursor to the cell surface (Briley et al., 1997; Urena et al., 1999) . However, the VV motif is not the only determinant of TGF-a tracking and subcellular distribution, because the naturally occurring variant precursors, which lack C-terminal Val residues but have dierent C-terminal protein motifs, are also expressed at the cell surface. This may indicate that tracking to the cell surface is controlled by dierent protein ± protein interactions for each TGF-a form, and raises the possibility that the interactions with the ErbBs we describe here may in¯uence tracking and distribution of the TGF-a precursors, as well as (possibly) signaling through the ErbBs.
Our current working hypothesis is that binding of the mature TGF-a moiety to its primary ErbB receptor, the EGF receptor, as well as the binding of its cytoplasmic domain to the intracellular domains of ErbB2 or ErbB4 may promote heterodimerization of the ErbB receptors. It is possible that dierent TGF-a forms may promote the formation of dierent heterodimers, which activate dierent pathways of signaling. Future studies are aimed at testing this possibility, and to further elucidate the functional consequences of TGF-a/ErbB interactions in the control of cell proliferation and TGF-a tracking.
Materials and methods

Chemicals, antibiotics, and cell lines
Puromycin, G418 and Zeocin were purchased from Sigma (St. Louis, MO, USA), GIBCO (Gaithersburg, MD, USA), and Invitrogen (Carlsbad, CA, USA), respectively. Monoclonal anti-HA antibody (clone 12CA5), rat anti-HA high anity monoclonal antibody (clone 3F10) and rat anti-HA HRP conjugate (clone 3F10) were purchased from Boehringer Mannheim (Indianapolis, IN, USA). Anti-b-actin monoclonal antibody (clone AC15) was obtained from Sigma. Anti-phosphotyrosine monoclonal antibody pY plus was obtained from Zymed (South San Francisco, CA, USA). Sheep anti-human EGF receptor antibody, mouse monoclonal anti-human EGFR antibody (clone LA1), and rabbit anti-human ErbB2 were purchased from Upstate Biotech Inc (Lake Placid, NY, USA). Rabbit anti-human ErbB3 (C-17) and anti-human ErbB4 (C-18) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
CHO K1 cells were obtained from ATCC (Rockville, MD, USA). CHO cells and derived transfectants were maintained in F12 medium containing 10% fetal bovine serum (FBS).
Plasmid construction and transfection
PCR-based site-mutagenesis (Xu et al., 1999) was used to generate mutants targeting the unique carboxyl-termini of the TGF-a precursors. On the template of pcDNA-HAWT, combinations of forward primer T7 and reverse primers TA.WTDV.A or TA.VVDEL.A (see sequence below) were employed to generate deletion mutants with the extreme carboxyl-terminal valine residue deleted, or both carboxylterminal valine residues deleted, respectively. The resulting plasmids were designated as pcDNAHA-WTDV and pcDNA-VVDEL. pcDNA-VVDEL encodes the common peptide sequences among the three TGF-a precursors. On the template of pcDNA-HAVaI, combinations of forward primer T7 and reverse primers TA. Chimeric constructs containing a Hook molecule with or without its transmembrane domain and the cytoplasmic domains without or with transmembrane domain of the TGF-a precursors were generated by two-step PCR-based mutagenesis (Xu et al., 1999) . The Hook molecule is derived from the pHook-2 construct (Invitrogen), which encodes a hapten-binding single-chain antibody (PhOx sFv) along with a signal peptide and a HA tag at its amino terminus, and two Myc tags and the PDGF receptor transmembrane domain as its carboxyl terminus. This Hook molecule, when overexpressed, displays a functional sFv on the cell surface. This Hook molecule was ampli®ed by PCR using the primers TAKIM5.s and HOOK3.A and subcloned into the BamHI site and EcoRI site of pcDNA3.1. The resulting plasmid was designated pcDNA-Hook. On the templates of the TGF-a expression constructs (WT, VaI, VaII, and VVDEL) in pcDNA3.1, the combinations of TACT.S or TMCT.S and the reverse vector primer cDNA.R produced fragments containing the cytoplasmic domain without or with transmembrane domain of TGF-a precursors respectively. On the same templates, the resulting PCR products in combination with the forward primer TAKIM5.S were used to amplify the chimeric fragments containing the Hook molecule without or with PDGFR transmembrane domain. The ®nal PCR products were subcloned into the BamHI site and EcoRI site of pcDNA3.1. The resulting plasmids were designated pcDNA-TACTWT, pcDNA-TACTVaI, pcDNA-TACTVaII, pcDNA-TACTVVDEL, pcDNA-TMCTWT, pcDNATMCTVaI, pcDNA-TMCTVaII, and pcDNA-TMCTV-VDEL. The sequences of the primers used were as follows: TAKIM5.S, 5'-GCT CGG ATC CGC CAC CAT GGA GAC AGA CAC ACT C-3' (nucleotides of a BamHI site are underlined); Hook3.A, 5'-CTG CAG AAT TCC TAA CGT GGC TTC TTC TG-3' (nucleotides of an EcoRI site are underlined); TACT.S, 5'-CTT TGG CAG AAG AAG CCA CGT CAC TGC TGC CAG GTC CGA AAA CAC-3'; TMCT.S, 5'-CAT CTC AGA AGA GGA TCT GAA TCA GGC CAT CAC CGC CTT GGT G-3', cDNA.R, 5'-TAG AAG GCA CAG TCG AGG-3'.
The full-length ErbB1 cDNA was released from pCO12-EGFR (Velu et al., 1987) and cloned in pcDNA3.1/Zeo (Invitrogen). The resulting construct was designated as pcDNA-WTEGFR/Zeo. pBabe-ErbB2, 3, 4 -puro retrovirus constructs were kindly provided by Dr Nancy Hynes (FMI, Switzerland). pBabe-puro empty vector was a kind gift from Dr Land (Morgenstern and Land, 1991) .
All the constructs were introduced into CHO cells or CHO cells expressing TGF-a precursors or mutants by the calcium phosphate precipitation method. The concentration of antibiotics used for selection was 500 mg/ml for G418, 300 mg/ml for Zeocin, and 20 mg/ml for puromycin.
Lysate preparation, immunoprecipitation, and Western blotting Lysate preparation has been described previously (Xu et al., 1999) . For detection of phosphorylated proteins and examination of the interactions in the absence or presence of serum, duplicate dishes of cells were cultured until 80% con¯uent and starved in serum-free medium for 24 h. On the following day one dish was used for lysate extract directly. The other dish was replaced with complete medium containing 10% FBS for 1 h, after which lysate was extracted. For detection of phosphorylated proteins, the lysis buer included 2 mM Na 3 VO 4 . For immunoprecipitation, 400 or 500 mg protein of total lysate was precipitated with appropriate amount of antibodies (4 mg for anti-ErbB1, 3 mg for antiErbB2, 2 mg for anti-ErbB3, and 2 mg for anti-ErbB4). The precipitates were washed in IP washing buer (1% deoxycholate, 0.1% SDS, 20 mM Tris, pH 7.5, 150 mM NaCl) four times and in PBS (®nal wash) once. The precipitates were then applied for Western analysis. Western analysis has been previously described (Xu et al., 1999) .
Immunofluorescence and confocal imaging of HA-tagged TGF-a Stable transfectants of HA-tagged TGF-a wild type, variant and VV deletion mutant constructs in CHO cells were grown on glass coverslips in F-12 medium supplemented with 10% FBS. The following day, the cells were rinsed in PBS and transferred to F-12 medium without serum for 12 h. Cells were then rinsed twice in PBS and ®xed in 3.7% formaldehyde in PBS. The cells were blocked for 30 min in PBS with 0.5% bovine serum albumin (BSA) and 5% normal goat serum. For permeabilized cells, 0.1% Triton X-100 was added to the blocking solution and all subsequent steps. The primary antibody, high-anity rat monoclonal anti-hemagglutinin (clone 3F10, Boehringer Mannheim), was added to cells at a ®nal concentration of 200 ng/ml, diluted in PBS with 0.1% BSA and 1% normal goat serum, for 1 h at room temperature. Cells were washed twice in PBS and incubated in secondary antibody, Alexa Fluor TM 488 goat anti-rat IgG (Molecular Probes) (4 mg/ml in PBS with 0.1% BSA and 1% normal goat serum), for 1 h at room temperature, followed by three 5 min washes in PBS. Fluorescence was visualized by the Bio-Rad MRC 1024 Laser Scanning Confocal Imaging System coupled to a Nikon Optiphot 1 confocal microscope; captured images were approximately 4 ± 8 microns above the coverslip.
Abbreviations BTC, b-cellulin; CHO, Chinese hamster ovary; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EPR, epiregulin; FBS, fetal bovine serum; HB-EGF, heparin-binding epidermal growth factor; IP, immunoprecipitation; NRG, neuregulin; PBS, phosphatebuered saline; PDZ, PSD-95/Dlg/ZO-1; RPA, ribonuclease protection assay; TGF-a, transforming growth factor a
